Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
DRI Healthcare Trust is a Canada-based investment trust focused on acquiring and managing pharmaceutical royalty interests and other healthcare-related revenue streams. The trust operates within the healthcare and life sciences investment industries, with a specialization in biopharmaceutical royalties tied to approved and commercial-stage therapies. Its primary revenue is generated from contractual royalty payments linked to the sales of prescription drugs and medical products marketed by third-party pharmaceutical companies.
The trust is positioned as a non-operating owner of healthcare royalties, allowing it to generate predictable, asset-backed cash flows without assuming clinical development or commercialization risk. DRI Healthcare Trust was established following the spin-out of royalty assets from DRI Capital Inc. and completed its initial public offering in 2020, listing on the Toronto Stock Exchange under the ticker DHT.UN (also traded as DHTU.TO). Since inception, the trust has expanded its portfolio through disciplined acquisitions of royalty and royalty-like interests.
Business Operations
DRI Healthcare Trust operates as a single investment-focused platform with diversified royalty interests across multiple therapeutic areas. Its core business consists of acquiring, holding, and managing pharmaceutical royalty assets that generate recurring income based on product sales. Revenue is derived primarily from cash royalties, milestone payments, and, in some cases, interest income from structured royalty financings.
The trust’s operations are global in nature, reflecting the international sales footprint of the underlying pharmaceutical products. DRI Healthcare Trust does not conduct research, development, or manufacturing activities and does not control the commercialization of the products tied to its royalties. The trust is externally advised by DRI Capital Inc., which provides sourcing, evaluation, and portfolio management expertise and plays a central role in identifying new investment opportunities.
Strategic Position & Investments
Strategically, DRI Healthcare Trust seeks to grow its cash flow and net asset value through the acquisition of high-quality royalty streams associated with marketed or late-stage biopharmaceutical products. Growth initiatives are centered on deploying capital into diversified royalty portfolios, often in partnership with drug developers, academic institutions, or other healthcare investors seeking non-dilutive financing solutions.
The trust has made multiple investments across a range of therapeutic categories, including oncology, rare diseases, neurology, and immunology. These investments are typically structured to provide long-duration revenue exposure while limiting downside risk. DRI Healthcare Trust benefits from the broader platform of DRI Capital Inc., which remains a significant strategic partner and has an established track record in global healthcare royalty investing.
Geographic Footprint
DRI Healthcare Trust is headquartered in Canada, with its principal office in Toronto, Ontario. While the trust itself maintains a centralized corporate presence, its economic exposure is international due to the global commercialization of the pharmaceutical products underlying its royalty portfolio.
The trust’s royalty revenues are generated across North America, Europe, and other international markets where partnered pharmaceutical companies sell approved therapies. This global revenue base provides geographic diversification and reduces reliance on any single healthcare system or regulatory environment.
Leadership & Governance
DRI Healthcare Trust is led by an executive team with extensive experience in healthcare finance, royalty investing, and capital markets. The leadership philosophy emphasizes disciplined capital allocation, risk-adjusted returns, and long-term income stability for unitholders, supported by rigorous due diligence and portfolio diversification.
Key executives include:
- Behzad Khosrowshahi – Chief Executive Officer
- Daniel Ifergan – Chief Financial Officer
Mr. Khosrowshahi is also the founder of DRI Capital Inc., the trust’s external manager, and has played a central role in shaping the trust’s strategic vision and investment approach.